Eli Lilly and Company (NYSE: LLY) and AstraZeneca yesterday announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. AZD3293, also known as LY3314814, has been shown in Phase I studies to reduce levels …read more.